Regression of metastatic, radiation/chemotherapy-resistant uterine serous carcinoma overexpressing HER2/neu with trastuzumab emtansine (TDM-1)

BACKGROUND: The management of uterine-serous-carcinoma (USC) no longer amenable to treatment with surgery, radiation and/or chemotherapy remains dismal. Alternative therapeutic options are desperately needed. CASE: We describe the case of a heavily pretreated 74-year-old patient with a recurrent USC...

Descripción completa

Detalles Bibliográficos
Autores principales: Santin, Alessandro D., Bellone, Stefania, Buza, Natalia, Schwartz, Peter E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2016
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5175991/
https://www.ncbi.nlm.nih.gov/pubmed/28018954
http://dx.doi.org/10.1016/j.gore.2016.12.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5175991/
https://www.ncbi.nlm.nih.gov/pubmed/28018954
http://dx.doi.org/10.1016/j.gore.2016.12.003

Ejemplares similares